

Anticancer bioactive peptide suppresses human gastric cancer growth through modulation of apoptosis and the cell cycle

LIYA SU^{1,2}, GUIHUA XU², JIE SHEN², YA TUO³, XINGGUANG ZHANG⁴,
SHUQIN JIA², ZHONG CHEN⁵ and XIULAN SU^{1,2}

¹Department of Cell Biology, Capital Medical University, Beijing; ²Clinical Medicine Research Center, Inner Mongolia Medical College and ³Department of Preventive Medicine, Inner Mongolia Medical College, Huhhot; ⁴Laboratory Testing Center, Inner Mongolia Medical College Affiliated Hospital, Huhhot, Inner Mongolia, P.R. China; ⁵Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, USA

Received August 4, 2009; Accepted September 15, 2009

DOI: 10.3892/or_00000599

Abstract. Anticancer bioactive peptide (ACBP) was extracted from goat spleens with immunization by human gastric cancer extracts. ACBP was biochemically purified and identified as ~8,000 Da peptide. Here we report that ACBP significantly inhibited the growth of human gastric cancer line BGC-823 *in vitro* in a dose-dependent manner. ACBP induced BGC-823 cell apoptosis was observed morphologically both by light microscopy and electronic microscopy; and ACBP-induced apoptosis and G₀/G₁ cell cycle arrest were quantified by Annexin V-FITC/PI staining and flow cytometry. At the molecular level, ACBP induced *p16^{Ink4}*, *p21^{Waf1}*, *p27^{Kip1}*, and *bax* tumor suppressor and apoptotic gene expression, as well as inhibited *cyclin D1*, *c-myc*, and *bcl-2* gene expression that promote tumorigenesis. *In vivo*, ACBP dramatically inhibited human gastric tumor growth in a xenograft model with no apparent cytotoxicity to host. Our study suggests that ACBP could be a powerful anticancer biological product through induction of cell apoptosis and cell cycle arrest.

Introduction

Gastric cancer currently ranks second in cancer mortality worldwide, with an especially high rate in Asia (1). In China, annual mortality is estimated to be as high as 16 per 100,000 population with gastric cancer accounting for the leading cause of death among malignant tumors (2). Due to distinct

discrepancies in diagnosis, prognosis, and treatment efficacy for gastric cancer patients with the same pathological staging, the traditional choice of surgery combined with palliative chemotherapy has not reached expected clinical efficacy. Development of novel therapeutic strategy is urgently required for the treatment of patients with advanced gastric cancer.

A broad spectrum of bioactive peptides exist in natural resources that involve different biological processes exhibiting regulatory activities. The identification of bioactive peptides with anticancer activity could be a new strategy to develop a novel anticancer therapeutic agent with low toxicity. Bioactive peptides refer to peptides with vital physiological effects, from either endogenous (from the host itself) or exogenous sources (from other hosts or natural products). Due to their effective absorption or delivery mechanisms, bioactive peptides exhibit more significant physiological functions than free amino acids. In addition, due to the nature of biological products, minimal toxicity would be expected for bioactive peptides when compared with classical chemotherapies or targeted therapy using small molecules. Alternatively, bioactive peptides could be used as new adjuvant agents to enhance chemotherapeutic efficacy and reduce toxicity in the treatment of cancer patients.

Anticancer bioactive peptide (ACBP) was identified from goat spleen extract after immunization with gastric cancer lysates in our laboratory. ACBP is a polypeptide with low molecular weight (~8,000 Da), which was enriched and purified by centrifugation, and microcolumn high-performance liquid chromatography (MHPLC) separation and purification. We previously observed that ACBP exhibited potent anti-neoplastic effect on mouse model with leukemia *in vivo*, as well as anticancer effects against human nasopharyngeal carcinoma *in vitro* (3-5). In addition, ACBP markedly inhibited tumor growth with few toxicity effects in long-term animal experiments (6,7). However, the molecular mechanisms of ACBP anticancer effects are not yet well understood.

Here we show the potent anticancer effects of ACBP against gastric cancer cell line BGC-823 *in vitro* through inhibition of cell proliferation. Such effect is mediated through the induction of cell apoptosis and cell cycle G₀/G₁ arrest.

Correspondence to: Dr Xiulan Su, Huhhot No. 1 Tongdao North Street, Huhhot, Inner Mongolia, 010050, P.R. China
E-mail: xlsu@hotmail.com

Dr Zhong Chen, Head and Neck Surgery Branch, NIDCD/NIH, 10/5D55, MSC-1419, Bethesda, MD, USA
E-mail: chenz@nidcd.nih.gov

Key words: bioactive peptide, gastric cancer, tumor growth, apoptosis, cell cycle

ACBP modulates several important gene expressions involved in cell growth and apoptosis. The inhibitory effect of ACBP on gastric cancer growth *in vivo* with minimal toxicity suggests that it could be a potential therapeutic agent that warrants further clinical investigation.

Materials and methods

Production and purification of ACBP. ACBP was produced and extracted using the following steps. Goats were immunized five times through a series of injections with human gastric cancer extracts. The spleens were harvested from the immunized animals and frozen and thawed three times. After centrifugation at 4,000 rpm for 10 min, the supernatants were collected and ACBP was isolated through MHPLC. Molecular weight of ACBP is ~8,000 Da based on measurement with SDS-PAGE gels (Fig. 1A). Anticancer bioactive peptide (ACBP) was an invention patent of our laboratory, protected by the Chinese National Patent Bureau, patent number: ZL96122236.0.

Cell culture. Gastric adenocarcinoma cell line BGC-823 was kindly provided by Professor Ke Yang (Beijing University, Health Center, Beijing, China). Cells were maintained in RPMI-1640 culture medium (Invitrogen, USA), which was supplemented with 10% heat-inactivated fetal bovine serum (FBS, TBD Science, China), 100 U/ml penicillin, and 100 U/ml streptomycin, and cultured in a humidified atmosphere of 5% CO₂ at 37°C.

MTT assay. Cell proliferation was measured by MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, TBD Science Co., China]. MTT was dissolved in sterile PBS at 5 mg/ml at room temperature, sterilized by passing through a 0.22 µm filter, and stored in the dark at 4°C. BGC-823 human gastric cells (5×10³/well) were placed in 200 µl of culture medium and incubated overnight. After 24 h, cultures were treated with 10, 15, 20 and 25 µg/ml of ACBP in triplicates. MTT reagent (20 µl) was added at different time points and then incubated at 37°C for 4 h. Following vibrating on a shaker for 10 min, the plates were measured for absorbance at 490 nm wavelength using a microtiter plate reader. The inhibiting rate (IR) of cell growth was expressed as (A-B)/A×100% (A, the absorbance values of controls groups; B, the absorbance values of experimental cells).

Haematoxylin-eosin staining. Cells were plated on sterile microscope coverslips to allow cell adhesion. After 24 h, cells were treated with 20 or 25 µg/ml ACBP. Cultured cells were sequentially taken out of the incubator at 24, 48 and 72 h, and washed with cold phosphate-buffered saline (PBS) for 3 times. Cells were fixed with glacial acetic acid and methanol at 1:3 ratio for 30 min, and stained by haematoxylin-eosin. Cell morphology was observed under a light microscope (Olympus, Tokyo, Japan).

Transmission electron microscope. BGC-823 cells were cultured in RPMI-1640 medium containing 15 µg/ml of ACBP for 48 h. All cells were fixed in 3% glutaraldehyde

and 2% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.4) at 4°C for 1 h, and then postfixed in 1% osmium tetroxide in the same buffer at 4°C for 1 h. After en bloc staining with 4% tannic acid and 0.5% uranyl acetate, the samples were dehydrated in graded concentrations of ethanol. The ultrathin sections were stained with uranyl acetate and lead citrate and examined with a JEM-1200EX transmission electron microscope (JEOL Co., USA) operated at 75 KV.

Apoptosis detection by staining with Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI). Cells were grown on 60-mm dishes and serum was deprived at exponential growth phase. ACBP was administrated for 24, 48 and 72 h (5 and 20 µg/ml). Then cells were harvested at different time points and stained with Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) for detection of apoptosis. The stained cells were examined using a FACSCalibur flow cytometry and data were analyzed by CellQuest software (Becton-Dickinson, CA, USA).

Cell cycle analysis. Cells were treated with 20 µg/ml ACBP and harvested 24, 48 or 72 h post treatment. Cells were incubated with 2 mg/ml RNase in PBS (200 µl) and 0.1 mg/ml propidium iodide (PI) in 0.6% Nonidet P-40 in PBS (200 µl) on ice for 30 min. Cell cycle was examined using a FACSCalibur flow cytometry and data were analyzed using CellQuest software (Becton-Dickinson).

Total RNA extraction and RT-PCR. BGC-823 cells were treated with 25 µg/ml ACBP for 24, 48 and 72 h, and total RNA was extracted from cells using TRIzol reagent (Invitrogen, USA) according to the manufacturer's protocol. The quality and concentrations of RNA were measured by a Du-70 UV spectrophotometer (Beckman, USA). Reverse transcription was performed using an RNA PCR Kit (AMV) Version 3.0 (Takara Co., Japan), and the reaction mixture contained: 2 µl RNA sample (1 µg/µl), 2 µl 10X buffer, 2 µl dNTP (1 mmol/l), 1 µl oligo-dT primer (0.125 µM), AMV RTase 20 U, RNase inhibitor 10 U and DEPC ddH₂O up to 20 µl. The mixture was kept at room temperature for 10 min, then, was incubated at 42°C for 30 min and at 95°C for 15 min. Reactions were stopped by cooling at 5°C for 5 min.

PCR was performed in 50 µl reaction mixture consisted of 10 µl reverse transcription products, 10 µl 5X buffer, 0.5 µl each gene specific primers (20 pmol/l), 1 µl 10 mM dNTP, 1.5U Taq DNA polymerase (Takara), with ddH₂O added up to 50 µl. PCR cycle parameters were conducted with a preamplification denaturation at 94°C for 5 min, followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 58-65°C for 30 sec, and extension at 72°C for 1.5 min, with a final extension at 72°C for 5 min. β-actin was used as an internal control. Amplified PCR products were visualized in a 2% agarose gel electrophoresis containing ethidium bromide. Ratios amplified gene/β-actin was calculated by software Imagetool 2.0 (University of Texas Health Science Center, San Antonio, TX, USA). PCR results were confirmed by three repeat amplifications. The sequences of PCR primers were designed using GenBank database and the BLAST




Figure 1. Molecular and biological characteristics of ACBP. (A) Purified ACBP was run on 12% SDS-PAGE gels, and the molecular weight is $\sim 8,000$ Da. M, marker; L, low concentration of ACBP ($1 \mu\text{g}/\mu\text{l}$); H, high concentration of ACBP ($2.5 \mu\text{g}/\mu\text{l}$). (B) ACBP suppressed BGC-823 gastric cancer cell proliferation in a time- and dose-dependent manner by MTT assay; the median concentration (IC_{50}) is $17.86 \mu\text{g/ml}$.

program. All primers were synthesized commercially by Takara Co.

Xenograft tumor model and administration of ACBP. Five-week-old athymic nude female mice (BALB/c nu/nu, Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences, Beijing, China) were housed in a sterile animal facility and inoculated with BGC-823 cells (5×10^6) in 0.1 ml of PBS subcutaneously. All mice developed single palpable tumors at day 3, following inoculation, and were randomized into control ($n=10$) and ACBP treated group ($n=10$). ACBP ($7 \mu\text{g}$) in 0.2 ml was injected via mouse tail vein, once every other day during a 2-week period and the control mice were injected with 0.2 ml of sterile PBS. Tumors were measured, and the animals bearing big tumors were followed for any signs of discomfort. After two weeks, mice were sacrificed, tumors were dissected, fixed in formalin, and embedded in paraffin. Sections were stained with hematoxylin and eosin. The experiments, and animal care were conducted according to the Institutional ethics guidelines.

Immunohistochemistry. Isolated tumors were immediately fixed with 4% paraformaldehyde, embedded in paraffin, and sectioned at a thickness of $4 \mu\text{m}$. PCNA protein expression in tissue was detected using SABC immunohistochemical method. After deparaffin, antigen retrieval was carried out in a microwave oven for 10 min. A rabbit anti-human PCNA polyclonal antibody was used at 1:100 dilution. Sections were stained with 3,3-diaminobenzidine (DAB), counterstained with haematoxylin, and dehydrated in xylene, and mounted. The immunohistochemical staining was observed under light microscope (Olympus).

Statistical analysis. Data are presented as the mean \pm standard deviation (SD). Statistical analysis was performed

using t-test for two groups, and two-way ANOVA for multiple comparisons; $p < 0.05$ was considered statistically significant. All statistical analyses were performed using the SPSS program (version 13.0).

Results

ACBP inhibited proliferation of cultured BGC-823 cancer cells. To determine the effect of ACBP on cell growth, BGC-823 cancer cells were treated with increasing concentrations of ACBP for 24, 48 and 72 h, and cell survival was assessed by MTT assay (Fig. 1B). As shown, ACBP (10.0 – $25.0 \mu\text{g/ml}$) treatment resulted in a concentration-dependent inhibition of cell proliferation. The survival of BGC-823 cancer cells was decreased by ~ 2.9 , 18.2 , 24.6 and 32.8% on a 24-h exposure to 10 , 15 , 20 , or $25 \mu\text{g/ml}$ ACBP, respectively (Fig. 1B). The median concentration (IC_{50}) was $17.86 \mu\text{g/ml}$. In addition, ACBP anti-proliferative effect on BGC-823 cells was persistent and increased with prolonged treating time. For example, a 48-h treatment of BGC-823 cancer cell with the $25 \mu\text{g/ml}$ concentration of ACBP resulted in a 64.5% decrease in cell viability, compared to a 32.8% decrease with 24-h exposure to the same concentration of ACBP (Fig. 1B).

ACBP induces cell apoptosis observed by light and electronic microscopies. The effect of ACBP on cell proliferation was further investigated, the ACBP induced significant morphological alteration of BGC-823 cancer cell (Fig. 2A). The control cells showed the characteristics of cancer morphology with irregularly multilateral shape, conspicuous karyosomes, and plentiful cytoplasm fraction. After treatment of ACBP for 48 h, the numbers of dividing cells were reduced significantly and a nucleus condensation and a low ratio of nucleus to cytoplasm were observed. In addition,




Figure 2. ACBP induced apoptosis and modulated gene expression of BGC-823 cells *in vitro*. (A) Morphological changes of BGC-823 cells observed after H&E stain under light microscopy. Blank control (1); 20 $\mu\text{g/ml}$ ACBP for 48 h (2); 25 $\mu\text{g/ml}$ ACBP for 48 h (3); 20 $\mu\text{g/ml}$ ACBP for 72 h (4); 25 $\mu\text{g/ml}$ ACBP for 72 h (5). Nuclear condensation, apoptotic features with nucleus fragments or dissolution is highlighted by arrows. (B) Morphological alteration of BGC-823 cells treated with 20 $\mu\text{g/ml}$ ACBP were observed under transmission electron microscope (x9000). Marked condensation of nuclear chromatin near the periphery (arrow heads) at late stage of apoptosis in the BGC-823 cells (1 and 2), in contrast to the high karyoplasmic ratio and the normal irregular shape of nuclei in control cells (3 and 4). (C) ACBP modulates gene expression of BGC-823 cells. BGC-823 cells were treated with 25 $\mu\text{g/ml}$ of ACBP and total RNAs were harvested at the time indicated. RT-PCR products were run on 2% agarose gel, and the representative gel images are shown with the indicated molecular weight. M, marker; B, blank control; N, cells treated with normal peptide; ACBP, cells treated with ACBP. (D) The proapoptotic gene *bax* was increased at 48 and 72 h, while the anti-apoptotic gene *bcl-2* was decreased at 72 h after treatment.

cellular volume was deflated distinctly and cells became round in shape. After treatment of 72 h, more apoptotic features with nucleus fragments, dissolution, or agglomeration (arrow) were observed (Fig. 2A).

ACBP-induced cell apoptosis was further demonstrated by electron microscopy, showing the characteristic apoptotic patterns in a greater number of BGC-823 cancer cells treated with 20 $\mu\text{g/ml}$ ACBP for 48 h (Fig. 2B). Ultrastructural apoptotic features in the nucleus and cytoplasm of the BGC-823 cancer cells were observed with irregular or fragmented shape nuclei. Chromatin was partially disrupted by the presence of nuclear vacuoles and part of chromatin appeared condensed near the periphery, close to the nuclear envelope in one or several large and homogeneous masses (Fig. 2B).

ACBP induces early apoptosis and cell cycle arrest measured by Annexin V-FITC/PI staining and flow cytometry. ACBP-induced early apoptosis of BGC-823 cells was further quantified by Annexin V-FITC/PI staining and flow cytometry. The apoptosis rate was enhanced with increased

doses of ACBP, from 5 to 15 $\mu\text{g/ml}$, and increased treatment time from 24-48 h (Table I, upper part). Persistent apoptosis was observed at both the 24- and 48-h time points, and optimal apoptosis (0.59%) was observed when cells were treated with 15 $\mu\text{g/ml}$ ACBP at 48 h, compared with the control (0.40%). We further determined the ACBP effect on cell cycle distribution by flow cytometry. Exposure of ACBP resulted in increasing percentages of G_0/G_1 in BGC-823 cells (Table I, lower part). Persistent cell cycle arrest was also observed and optimal G_0/G_1 arrest (68.8%) occurred when 20 $\mu\text{g/ml}$ ACBP was added for 72 h, whereas the corresponding values in the untreated control group was 52.6%.

*ACBP treatment increases $p16^{\text{Ink4}}$, $p21^{\text{Waf1}}$, $p27^{\text{Kip1}}$, *bax* and decreases *cyclin D1*, *c-myc*, *bcl-2* mRNA expression.* To evaluate the molecular mechanism regulated by ACBP, we analyzed a panel of important genes by semi-quantitative RT-PCR. The genes include tumor suppressor genes, such as $p16^{\text{Ink4}}$, $p21^{\text{Waf1}}$, and $p27^{\text{Kip1}}$; genes involved in apoptosis pathway, such as *Bax* and *Bcl-2*; and genes controlling cell

SPANDIDOS PUBLICATIONS effects of ACBP on cell cycle of BGC-823 (%; mean \pm SD).

BGC-823	Group	24 h	48 h	72 h
Apoptosis	Control	0.36 \pm 0.015	0.40 \pm 0.055	
	ACBP (5 μ g/ml)	0.42 \pm 0.059 ^a	0.56 \pm 0.451 ^a	
	ACBP (15 μ g/ml)	0.53 \pm 0.067 ^b	0.59 \pm 0.153 ^b	
Cell cycle	Control			
	G ₀ /G ₁	56.9 \pm 2.3	51.1 \pm 6.2	52.6 \pm 5.0
	S	32.9 \pm 2.0	41.0 \pm 8.6	33.7 \pm 2.2
	G ₂ /M	9.6 \pm 3.9	7.7 \pm 2.4	13.6 \pm 2.8
	ACBP (20 μ g/ml)			
	G ₀ /G ₁	66.4 \pm 19.2 ^a	65.9 \pm 7.1 ^b	68.8 \pm 0.7 ^b
	S	26.9 \pm 11.5 ^a	26.7 \pm 7.1 ^b	26.1 \pm 1.3 ^b
	G ₂ /M	7.1 \pm 8.2 ^a	7.3 \pm 0.6	5.0 \pm 0.9 ^a

^ap<0.05; ^bp<0.01.




Figure 3. ACBP suppresses tumor growth *in vivo*. (A) Tumors were harvested after treated with ACBP (ACBP, n=10) and compared with controls (NS, n=10). (B) Tumor size were measured, calculated and presented as mean \pm standard errors (SE). The statistical significance was observed (p=0.01). (C) HE staining of tumor specimens harvested from *in vivo* experiments. More tumor cells with apoptotic features were detected in ACBP-treated group (right) when compared with control (left). (D) ACBP suppressed PCNA protein expression by IHC in tumors with ACBP treatment treated groups (right), when compared with control groups (left). The micrographs were take under light microscopy with x400 magnification.

cycle and proliferation, such as *cyclin D1* and *c-myc* (Fig. 2C). To test the gene expression, BGC-823 cells were treated with 20 μ g/ml ACBP for 24, 48 and 72 h, and compared with cells without treatment (B, blank controlled group) and cells treated with normal spleen peptide (N, negative control). Compared with cells treated with normal spleen peptide, *p16^{Ink4}* expression was increased at 24 and 48 h after treat-

ment and *p21^{Waf1}* expression was increased at 72 h, while no significant change of *p27^{Kip1}* expression was observed. Decreased *cyclin D1* was observed at 48 and 72 h after treatment, while decreased *c-myc* expression was observed only at 72 h. Furthermore, the proapoptotic gene *bax* was increased at 48 and 72 h, while the anti-apoptotic gene *bcl-2* was decreased at 72 h after treatment (Fig. 2D).

ACBP suppresses gastric tumor growth in a xenograft tumor model. The biological activity of ACBP was tested in a xenograft model *in vivo* with inoculation of gastric BGC-823 cancer cells. Compared with the controls, ACBP significantly suppressed tumor growth by 67% ($p=0.01$, Fig. 3A). The quality of life of tumor-bearing animals in the treated group was significantly improved over that of the control group. The mice in the treated group were more active, had good appetite, and their appearance and body weight were close to that of a normal mouse. Pathology analysis of harvested tumors showed more cells with apoptotic features in ACBP treated group (left, control group: 1.90 ± 1.59 ; right, ACBP group: 4.19 ± 2.02 ; $p<0.001$, Fig. 3C). The proliferation index by immunostaining of PCNA of the tumor cells was significantly decreased in the treated group (left, control group: 38.87 ± 1.98 ; right, ACBP group: 49.72 ± 1.82 $p<0.001$, Fig. 3D).

Discussion

In this study, we observed anticancer effect of ACBP through inhibition of the human gastric cancer cell line BGC-823 proliferation *in vitro* (Fig. 1B). The most potent effect reached 84.4% inhibitory rate, when treated with ACBP at the concentration of 25 $\mu\text{g/ml}$ for 72 h, which was concentration and time-dependent (Fig. 1B). The ACBP-treated cells exhibited typical morphological features of cell apoptosis when compared with typical cancer cell morphology of control cells under light microscope and electron microscope, suggesting that the anticancer effect of ACBP was due to induction of apoptosis (Fig. 2A and B). Quantitational analysis by flow cytometry of apoptosis further supported the observation (Table I). In addition, cell cycle analysis revealed that ACBP stopped BGC-823 cells at G_0/G_1 phase and decreased cells at S phase (Table I), indicating that ACBP might modulate the cell cycle checkpoints and block DNA synthesis.

The molecular mechanisms of ACBP induced apoptosis and cell cycle arrest were further assessed by gene expression controlling these biological activities. Oncogene *c-myc*, and genes involved in apoptotic process, *bcl-2* and *bax* are critical molecules controlling gastric carcinogenesis, as well as many other solid tumors (8,9). The increased expressions of *c-myc* and *bcl-2*, and the decreased expressions of *bax* are considered biomarkers of many cancers from epithelial origins, including gastric cancer (10-13). Li *et al.* (14) reported that abnormal *c-myc* and *bcl-2* expression are important factors in gastric carcinoma development; that overexpression of *c-myc* and *bcl-2* corporately inhibit the apoptotic pathways. Decreased *bax* protein expression has been identified in the progress of various human malignant tumors (15-17). Our study is consistent with others that ACBP induces gastric cancer cell apoptosis through regulating the critical gene expression.

The anticancer effects of ACBP are also mediated through the modulation of gene expression involved in cell cycle regulatory proteins (*cyclin D1*, *p16^{Ink4}*, *p21^{Waf1}*, and *p27^{Kip1}*, Fig. 2C and D). ACBP resulted in a significantly decreased expression of *cyclin D1* and a markedly increased expression of *p16^{Ink4}*, *p21^{Waf1}* and *p27^{Kip1}*, that are important molecules

modulating the universal process of cell dividing and participating in organism growth and development (18-20). Cell cycle progression is regulated by three functional classes of proteins, the cyclins, cyclin-dependent kinases (CDKs), and cyclin-dependent kinase inhibitors (CDKIs) (21,22). These molecules play critical roles in DNA synthesis and cell division, that alterations in their function may lead to the disruption of normal cell growth and apoptosis, and subsequently, result in carcinogenesis (23). Thus, ACBP inhibition of cancer cell growth is achieved by downregulation of cyclin D (Fig. 2C and D). In addition, ACBP upregulated cell cycle inhibitors, such as *p16^{Ink4}*, *p21^{Waf1}*, and *p27^{Kip1}*, which form cyclin-cdk complexes to regulate key checkpoints at the G_1/S phase of cell cycle and control cell growth (24,25). Furthermore, ACBP decreased cells in S phase and suppressed PCNA expression, which suggest that a decreased DNA synthesis might also be involved (Table I and Fig. 3D).

The potent anti-tumor growth activity of ACBP was observed *in vivo*, with consistent findings of *in vitro* study; that ACBP induced apoptosis and clock cell proliferation (Fig. 3). Our study suggests that the bioactive peptides with anticancer activity could be a novel strategy to develop therapeutic agents with low toxicity. There is a broad spectrum of bioactive peptides developed for targeting various diseases through different applications. For example, Artemisinin is a natural product isolated from *Artemisia annua L.* Oh *et al.* reported that the artemisinin-peptide conjugates showed potent anticancer activity against Molt-4 leukemia cells with a significantly improved cancer/normal cells selectivity (26). Pep42, a cyclic 13-mer oligopeptide that specifically binds to glucose-regulated protein 78 (GRP78) and internalizes into cancer cells, represents an excellent vehicle for tumor cell-specific chemotherapy (27). In addition, the non-immunogenicity of micro-peptides, especially of dipeptides and tripeptides, shows biological effects and ensures that consumers are free of anaphylaxis (28). Furthermore, peptide-based vaccines, one of several anti-tumor immunization strategies, can elicit both MHC Class I-restricted CD8⁺ and Class II-restricted CD4⁺ cellular responses (29).

In conclusion, we showed in this study that ACBP potently inhibited gastric cell proliferation *in vitro* and suppressed tumor growth *in vivo*. ACBP induced cell apoptosis and blocked cell cycle through decrease of *cyclin D1*, *c-myc*, *bcl-2* gene and PCNA protein expression, and increased *p16^{Ink4}*, *p21^{Waf1}*, *p27^{Kip1}*, and *bax* expression. Our preclinical study of ACBP suggests that ACBP modulates critical molecules controlling cell cycle and apoptosis, which could be developed as a new therapeutic approach against gastric neoplasms.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (No. 30860327, China), Major Project of Inner Mongolia Medical College (No. ZD9809, China), and NIH/NIDCD intramural research projects Z01-DC-000016 (USA). We thank Dr Ke Yang (Beijing University Medical Health Center) for helpful discussions and for providing cells lines. We also thank Cindy Clark (NIH library) for helpful revision of the manuscript.

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. *CA Cancer J Clin* 55: 74-108, 2005.
2. Sun XD, Mu R, Zhou YS, *et al*: Analysis of mortality rate of stomach cancer and its trend in twenty years in China. *Zhonghua Zhong Liu Za Zhi* 26: 4-9, 2004.
3. Su XL, Ke Y, Yan MR, Chen CH, Qing P and Ying S: The experimental research on anti-gastric cancer active peptide. *Int J Moden Cancer Ther* 2: 26-27, 1999.
4. Hou JF, Yan MR, Rong YN, Jiao TM and Su XL: Effect of anti-cancer bioactive peptide on leukemia mice. *Acta Academiae Med Neimongol* 26: 3-6, 2004.
5. Zhao YY, Peng SD and Su XL: Effects of anti-cancer bioactive peptide on cell cycle in human nasopharyngeal carcinoma strain CNE. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 41: 607-611, 2006.
6. Yan MR, Su XL and Liu QP: Effect of anti-gastric cancer biological peptide on lactic dehydrogenase isoenzyme. *China J Cancer Prev Treat* 9: 382-383, 2002.
7. Quan XH and Xiu LS: Effect of anti-gastric cancer biological peptide on mice and induction of TNF. *Chin J Cancer Biother* 12: 301-302, 2005.
8. Kountouras J, Zavos C and Chatzopoulos D: New concepts of molecular biology on gastric carcinogenesis. *Hepatogastroenterology* 52: 1305-1312, 2005.
9. Milne AN, Sitarz R, Carvalho R, Carneiro F and Offerhaus GJ: Early onset gastric cancer: on the road to unraveling gastric carcinogenesis. *Curr Mol Med* 7: 15-28, 2007.
10. Sumi T, Tsuneyoshi N, Nakatsuji N and Suemori H: Apoptosis and differentiation of human embryonic stem cells induced by sustained activation of c-Myc. *Oncogene* 26: 5564-5576, 2007.
11. Arnoult D: Apoptosis-associated mitochondrial outer membrane permeabilization assays. *Methods* 44: 229-234, 2008.
12. Nemec KN and Khaled AR: Therapeutic modulation of apoptosis: targeting the BCL-2 family at the interface of the mitochondrial membrane. *Yonsei Med J* 49: 689-697, 2008.
13. Xiang TX, Li Y, Jiang Z, *et al*: RNA interference-mediated silencing of the Hsp70 gene inhibits human gastric cancer cell growth and induces apoptosis in vitro and in vivo. *Tumori* 94: 539-550, 2008.
14. Li XL, Hao YR, Zou JX, Yang JH and Geng JH: Relationship between C-myc and Bcl-2 alterations and biological behavior and apoptosis in gastric cancer. *Xin Xiaohuabingxue Zazhi* 5: 773-774, 1997.
15. Kato K, Kawashiri S, Yoshizawa K, Kitahara H and Yamamoto E: Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas. *J Oral Pathol Med* 37: 364-371, 2008.
16. Lima MA, Ferreira MV, Barros MA, *et al*: Relationship between EBV infection and expression of cellular proteins c-Myc, Bcl-2, and Bax in gastric carcinomas. *Diagn Mol Pathol* 17: 82-89, 2008.
17. Liu FS, Jan YJ, Lai CR, *et al*: Expression analysis of apoptosis-related markers TP53, BCL-2, BAX and c-MYC in female genital tract sarcomas. *J Chin Med Assoc* 71: 628-634, 2008.
18. Cheng T: Cell cycle inhibitors in normal and tumor stem cells. *Oncogene* 23: 7256-7266, 2004.
19. Coffman JA: Cell cycle development. *Dev Cell* 6: 321-327, 2004.
20. Grzelakowska-Sztartabert B: Cell cycle checkpoints, molecular background. *Folia Morphol (Warsz)* 63: 1-3, 2004.
21. Lukas J, Lukas C and Bartek J: Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. *DNA Repair (Amst)* 3: 997-1007, 2004.
22. Murray AW: Recycling the cell cycle: cyclins revisited. *Cell* 116: 221-234, 2004.
23. Johansson M and Persson JL: Cancer therapy: targeting cell cycle regulators. *Anticancer Agents Med Chem* 8: 723-731, 2008.
24. Sherr CJ: Mammalian G1 cyclins and cell cycle progression. *Proc Assoc Am Physicians* 107: 181-186, 1995.
25. Sherr CJ: The Pezcoller lecture: cancer cell cycles revisited. *Cancer Res* 60: 3689-3695, 2000.
26. Oh S, Kim BJ, Singh NP, Lai H and Sasaki T: Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. *Cancer Lett* 274: 33-39, 2009.
27. Yoneda Y, Steiniger SCJ, Capkova K, *et al*: A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy. *Bioorgan Medicin Chem Lett* 18: 1632-1636, 2008.
28. Sarkar C, Singh SK, Mandal SK, *et al*: Human placental protein/peptides stimulate melanin synthesis by enhancing tyrosinase gene expression. *Mol Cell Biochem* 285: 133-142, 2006.
29. Mirshahidi S, Kramer VG, Whitney JB, *et al*: Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. *Vaccine* 27: 1825-1833, 2009.